



Press release from Emotra AB (publ)  
Göteborg, April 16, 2014

## Status for Our Planned Clinical Study

**Emotra is pleased to announce that our kick-off meeting in Rome was carried out as planned on April 14–15, 2014. Approximately 30 participants representing 17 clinics in nine European countries met and agreed on the importance of carrying out the planned clinical trials for EDOR, our suicide risk evaluation method. A large part of the meeting was dedicated to training the participants on how to use the method. Several clinics have received the green light from their respective ethical committees and are thereby able to initiate their trials. We estimate that the study will be completed in spring 2016. Once Emotra has achieved sufficiently strong scientific backing, we will initiate our market launch.**

17 of the 19 clinics that have signed co-operation agreements with Emotra participated in this kick-off. The participants consisted of opinion-leading researchers/clinics in suicide studies in Europe. The participants all agreed on the need to produce a clinically functional diagnostic method of determining the suicide risk of depressed people.

Agreement was also reached on the final design and wording of the clinical trial protocol, with an emphasis on Emotra's strategic decision to ally with leading opinion-makers in the field for marketing this new technology towards the health care sector. A publishing committee, with six representatives, was appointed and assigned the task of establishing guidelines for future publications as well as principles for spreading information about the results of the trials.

### **Approvals from Ethical Committees and Initiating the Trials**

Several clinics informed us that they have received approvals from their respective local ethical committees. Emotra provided these clinics with complete product systems so that they could start testing patients immediately. Other clinics informed us that they are far along in the approval process and expect to receive their respective ethical committee approvals in May/June 2014.

The clinics that in the past few weeks have agreed to take part in the study are in the process of composing their applications to their respective ethical committees. However, with help from those clinics that have already submitted applications, they should soon be able to submit their own applications. The two clinics that were not able to attend the kick-off meeting have already submitted their ethical committee applications and will receive training in the near future. It is the Board's opinion that the four new clinics, on top of the originally planned 15, will not cause any significant delay in the establishment of the trial results. Our goal is to finish these trials in spring 2016.

*"Emotra has entered a dynamic phase with an increasing number of clinical partners. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. Once Emotra's method has received sufficiently strong scientific backing from the clinics evaluating EDOR, we can initiate a launch of the method in Europe", says Company CEO Claes Holmberg.*

### **For further information, please contact:**

*Claes Holmberg, CEO  
Telephone: +46 708 25 45 47  
E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

---

**Emotra AB** is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.